^
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
06/10/2024
Initiation :
06/22/2016
Primary completion :
12/31/2024
Completion :
12/31/2024
ROS1
|
ALK positive • ROS1 rearrangement
|
everolimus • Zykadia (ceritinib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
06/07/2024
Initiation :
07/25/2019
Primary completion :
07/21/2021
Completion :
09/21/2024
MET
|
ALK positive • MET amplification • ALK rearrangement
|
cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
Phase 2
Hunan Province Tumor Hospital
Recruiting
Last update posted :
06/04/2024
Initiation :
04/16/2020
Primary completion :
12/24/2026
Completion :
12/24/2027
EGFR • BRAF • ALK • ROS1
|
EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
|
cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Active, not recruiting
Last update posted :
05/08/2024
Initiation :
02/01/2019
Primary completion :
04/01/2025
Completion :
04/01/2025
PD-L1
|
docetaxel • Zykadia (ceritinib)
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Active, not recruiting
Last update posted :
04/30/2024
Initiation :
06/27/2018
Primary completion :
10/28/2022
Completion :
08/01/2024
PD-L1 • BRAF
|
BRAF mutation • BRAF V600
|
Mekinist (trametinib) • Zykadia (ceritinib)
Phase 2
Giselle Sholler
Recruiting
Last update posted :
04/08/2024
Initiation :
09/01/2015
Primary completion :
09/01/2030
Completion :
09/01/2035
MYCN
|
MYCN amplification
|
dasatinib • sorafenib • Zykadia (ceritinib) • Zolinza (vorinostat)
Phase 2
Giselle Sholler
Recruiting
Last update posted :
04/08/2024
Initiation :
09/14/2022
Primary completion :
09/01/2026
Completion :
09/01/2033
MYCN
|
MYCN amplification
|
Zykadia (ceritinib) • Danyelza (naxitamab-gqgk)
Phase 3
Novartis Pharmaceuticals
Completed
Last update posted :
01/24/2024
Initiation :
07/09/2013
Primary completion :
06/24/2016
Completion :
01/07/2024
ALK
|
ALK positive
|
cisplatin • carboplatin • Zykadia (ceritinib) • pemetrexed
Phase 3
Novartis Pharmaceuticals
Completed
Last update posted :
11/30/2023
Initiation :
06/28/2013
Primary completion :
01/26/2016
Completion :
11/10/2023
ALK
|
ALK positive
|
Xalkori (crizotinib) • docetaxel • Zykadia (ceritinib) • pemetrexed
Phase 2
Ariad Pharmaceuticals
Active, not recruiting
Last update posted :
08/25/2023
Initiation :
01/31/2019
Primary completion :
09/30/2020
Completion :
06/28/2024
ALK
|
ALK rearrangement
|
Alecensa (alectinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
Phase 1
Roswell Park Cancer Institute
Completed
Last update posted :
07/25/2022
Initiation :
01/08/2015
Primary completion :
12/27/2018
Completion :
02/12/2019
ALK
|
cisplatin • gemcitabine • Zykadia (ceritinib) • albumin-bound paclitaxel
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/19/2020
Initiation :
06/01/2012
Primary completion :
01/01/2016
Completion :
01/01/2016
ALK
|
ALK translocation
|
Zykadia (ceritinib)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/17/2020
Initiation :
05/14/2015
Primary completion :
09/26/2018
Completion :
09/26/2018
ALK
|
ALK positive • ALK rearrangement
|
Zykadia (ceritinib) • Kisqali (ribociclib)
Phase 2
Novartis Pharmaceuticals
Completed
Last update posted :
12/16/2020
Initiation :
01/20/2015
Primary completion :
10/15/2019
Completion :
10/15/2019
BRAF
|
Piqray (alpelisib) • Mektovi (binimetinib) • Zykadia (ceritinib) • Tabrecta (capmatinib) • luminespib (AUY922)
Phase 1
St. Joseph's Hospital and Medical Center, Phoenix
Completed
Last update posted :
12/11/2020
Initiation :
02/17/2016
Primary completion :
11/29/2018
Completion :
07/12/2019
CASP3
|
Zykadia (ceritinib)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
06/09/2020
Initiation :
08/28/2013
Primary completion :
04/26/2019
Completion :
04/26/2019
ALK
|
Zykadia (ceritinib)
Phase 1/2
University of Washington
Withdrawn
Last update posted :
10/10/2019
Initiation :
01/03/2018
Primary completion :
07/01/2023
Completion :
07/01/2023
ALK
|
ALK positive
|
Zykadia (ceritinib) • Adcetris (brentuximab vedotin)
Phase 2
University of Texas Southwestern Medical Center
Withdrawn
Last update posted :
07/30/2019
Initiation :
06/01/2015
Primary completion :
01/01/2019
Completion :
01/01/2019
ALK
|
ALK mutation
|
Zykadia (ceritinib)
Phase 2
Novartis Pharmaceuticals
Completed
Last update posted :
03/26/2019
Initiation :
12/20/2012
Primary completion :
01/22/2018
Completion :
01/22/2018
ALK
|
ALK rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
03/15/2019
Initiation :
01/24/2011
Primary completion :
05/03/2016
Completion :
05/03/2016
ALK
|
ALK translocation
|
Zykadia (ceritinib)
Phase 1/2
Novartis Pharmaceuticals
Completed
Last update posted :
02/20/2019
Initiation :
03/07/2014
Primary completion :
07/27/2017
Completion :
07/27/2017
ALK
|
ALK positive • ALK rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib)
Phase 2
Yonsei University
Unknown status
Last update posted :
01/11/2019
Initiation :
07/24/2018
Primary completion :
05/01/2020
Completion :
10/01/2020
BRAF • ROS1
|
ROS1 rearrangement
|
Zykadia (ceritinib)
Phase 2
Yonsei University
Unknown status
Last update posted :
01/11/2019
Initiation :
09/01/2013
Primary completion :
12/01/2019
Completion :
12/01/2019
ROS1
|
ROS1 rearrangement
|
Zykadia (ceritinib)
Phase 2
Novartis Pharmaceuticals
Completed
Last update posted :
06/19/2017
Initiation :
11/26/2012
Primary completion :
03/29/2016
Completion :
03/29/2016
ALK
|
ALK rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib)